The growing availability of active agents makes the development of novel therapies increasingly complex and the choice of end points critical. We assessed the frequency of use of efficacy end …

Nov 10, 2018 · Purpose: To provide evidence-based consensus recommendations on choice of end points for clinical trials in metastatic breast cancer, with a focus on biologic subtype and line of therapy.

Mar 31, 2020 · Seidman AD, Bordeleau L, Fehrenbacher L, et al. National Cancer Institute Breast Cancer Steering Committee Working Group report on meaningful and appropriate endpoints for …

Considering the use of progression-free survival (PFS) and other surrogate endpoints in clinical trials, we must understand patient perspectives on measures used to assess treatment efficacy.

Mar 26, 2020 · In oncology, surrogate endpoints, especially progression-free survival (PFS), are frequently used as primary endpoints in place of overall survival (OS), the most clinically meaningful...

Dec 10, 2015 · Although therapeutics have been approved based on progression-free survival (PFS), its use as a primary end point is controversial. We aimed to assess to what extent PFS may be used as …

This review explores drivers that led to advances in treatment options, the validity of progression-free survival (PFS) and overall survival (OS) endpoints in clinical studies, and the clinical relevance of …

Apr 3, 2020 · Earlier studies suggest progression-free survival (PFS) may be used as a surrogate endpoint for overall survival (OS) in metastatic breast cancer, which could shorten follow-up duration …

Jun 1, 2016 · The gold standard end point in randomized clinical trials in metastatic breast cancer (MBC) is overall survival (OS). Although therapeutics have been approved based on progression-free …

We aimed to identify all studies evaluating the validity of PFS as a surrogate for OS in oncology, and to describe their methodological characteristics.